Company news

Arch Biopartners, Inc. news in 2026

Arch Biopartners, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Arch Biopartners Arranges Non-Brokered Private Placement

November 6, 2026

Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide

August 31, 2026

Arch Biopartners to Expand Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial to the United States

August 11, 2026

Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program

July 17, 2026

Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans

June 4, 2026

Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial

May 22, 2026

Royal Columbian Hospital begins patient recruitment in Arch Biopartners' Phase II trial of LSALT peptide targeting CS-AKI

April 30, 2026

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

March 24, 2026

Arch Biopartners Announces St. Michael's Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide

March 20, 2026

Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

February 9, 2026

Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board

January 16, 2026

Decks in 2026